male-dr

Leading the world in
early cancer detection research

Our innovative cancer screening
studies mean better outcomes for patients

female-dr

Innovation in cancer research
and development

We are changing the face of cancer detection
and treatment using the latest
advancements in Metabolomics

female-dr

Non-invasive and affordable early
cancer screening and monitoring
solution

90% of cancers are curable if caught early
Your Health is Our Focus!

Early cancer detection research for a better future

BIOMARK’S MISSION

To provide universal access to a new paradigm in cancer diagnostics using metabolomics.

WHAT IS A BIOMARKER?

According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:

  • proteins (e.g. an enzyme or receptor)
  • nucleic acids (e.g. a microRNA or other non-coding RNA)
  • antibodies
  • and peptides among other categories

A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.

POTENTIAL CLINICAL USES OF CANCER BIOMARKERS

Biomarkers have many potential applications in oncology including:

  • Estimating risk of cancer
  • Screening for occult primary cancers
  • Distinguishing benign from malignant findings or one type of malignancy from another
  • Monitoring status of the disease either to detect recurrence or determine response or progression to therapy
  • Personalizing a treatment program especially for immunotherapy applications
  • Help in assessing pseudo progression with imaging modalities

VIDEOS: CANCER EDUCATION

LATEST NEWS

Artificial Intelligence Positioned to Be a Game-Changer

6

Jul, 2017

Artificial Intelligence Positioned to Be a Game-Changer

By: | Tags:

Artificial Intelligence Positioned to Be a Game-Changer https://www.cbsnews.com/news/artificial-intelligence-positioned-to-be-a-game-changer/ It might not be long before machines begin thinking for themselves -- creatively, independently, and sometimes with better judgment than a human It might not be long before machines begin thinking…

READ MORE
A supramolecular indicator displacement assay for acetyl amantadine

29

Nov, 2016

A supramolecular indicator displacement assay for acetyl amantadine

By: | Tags:

A supramolecular indicator displacement assay for acetyl amantadine, a proxy biomarker for spermidine/spermine N1-acetyltransferase (SSAT) activity Introduction Cancer is a leading cause of death worldwide.1 The number of new cancer cases is expected to increase 40% in the next 15 years in Canada due to an aging and growing population.2 Lung cancer is the most commonly diagnosed in this country (excluding nonmelanoma skin cancers) and accounts for 14% of all…

READ MORE

NEWS RELEASES

Dr. Ian Smith Joins BioMark's Board of Directors

December 5, 2017

Vancouver, British Columbia – (December 5th, 2017)–BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Dr. Ian Smith has been elected to become a board director of the company. Rashid Ahmed, President and CEO, says, “We are extremely excited to welcome Dr. Smith to our board. His achievements in medical research space will be a major asset to BioMark.  Dr. Smith’s diagnostic expertise, leadership and research experience brings depth and practicality as we begin to commercialize and position our technology for different oncology applications […]


READ MORE

STOCK QUOTE

BIOMARK AWARDS, GRANTS, RECOGNITIONS

BioMark has been funded by various government agencies including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta since 2006. New research applications to Genome Canada and Genome BC Strategic Innovation Program were submitted in 2017 reviewed by peer groups. Now BioMark is collaborating with Bio banks across Canada to expand our metabolomics study.

Read More